188 related articles for article (PubMed ID: 34745002)
21. Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease.
Kemeny HR; Elsamadicy AA; Farber SH; Champion CD; Lorrey SJ; Chongsathidkiet P; Woroniecka KI; Cui X; Shen SH; Rhodin KE; Tsvankin V; Everitt J; Sanchez-Perez L; Healy P; McLendon RE; Codd PJ; Dunn IF; Fecci PE
Clin Cancer Res; 2020 Mar; 26(5):1141-1151. PubMed ID: 31744830
[TBL] [Abstract][Full Text] [Related]
22. Regulating effect of MMP-9 and TIMP-1 in pituitary adenoma invasion.
Mao JH; Guo H; Si N; Qiu L; Guo LF; Sun ZS; Xiang Y; Yang XH; Zhao WG; Zhang WC
Genet Mol Res; 2015 Dec; 14(4):17091-8. PubMed ID: 26681056
[TBL] [Abstract][Full Text] [Related]
23. Polysialylated neural cell adhesion molecules expressed in human pituitary tumors and related to extrasellar invasion.
Trouillas J; Daniel L; Guigard MP; Tong S; Gouvernet J; Jouanneau E; Jan M; Perrin G; Fischer G; Tabarin A; Rougon G; Figarella-Branger D
J Neurosurg; 2003 May; 98(5):1084-93. PubMed ID: 12744370
[TBL] [Abstract][Full Text] [Related]
24. Recurrence in pituitary adenomas in childhood and adolescence.
Espay AJ; Azzarelli B; Williams LS; Bodensteiner JB
J Child Neurol; 2001 May; 16(5):364-7. PubMed ID: 11392522
[TBL] [Abstract][Full Text] [Related]
25. MicroRNAs and Target Genes in Pituitary Adenomas.
Feng Y; Mao ZG; Wang X; Du Q; Jian M; Zhu D; Xiao Z; Wang HJ; Zhu YH
Horm Metab Res; 2018 Mar; 50(3):179-192. PubMed ID: 29351706
[TBL] [Abstract][Full Text] [Related]
26. Atypical pituitary adenomas: incidence, clinical characteristics, and implications.
Zada G; Woodmansee WW; Ramkissoon S; Amadio J; Nose V; Laws ER
J Neurosurg; 2011 Feb; 114(2):336-44. PubMed ID: 20868211
[TBL] [Abstract][Full Text] [Related]
27. Nonfunctioning Pituitary Adenoma Recurrence and Its Relationship with Sex, Size, and Hormonal Immunohistochemical Profile.
Batista RL; Trarbach EB; Marques MD; Cescato VA; da Silva GO; Herkenhoff CGB; Cunha-Neto MB; Musolino NR
World Neurosurg; 2018 Dec; 120():e241-e246. PubMed ID: 30138730
[TBL] [Abstract][Full Text] [Related]
28. Accurate assessment of estrogen receptor profiles in non-functioning pituitary adenomas using RT-digital PCR and immunohistochemistry.
Hattori Y; Ishii H; Tahara S; Morita A; Ozawa H
Life Sci; 2020 Nov; 260():118416. PubMed ID: 32926922
[TBL] [Abstract][Full Text] [Related]
29. Assessment of sFRP4 as a bio-marker for predicting aggressiveness and recurrence of growth hormone-secreting pituitary adenomas.
Wu Y; Liu C; Yu S; Gao H; Li Z; Li C; Zhang Y
Oncol Rep; 2016 May; 35(5):2991-9. PubMed ID: 26935389
[TBL] [Abstract][Full Text] [Related]
30. Increased TIGIT expressing NK cells with dysfunctional phenotype in AML patients correlated with poor prognosis.
Liu G; Zhang Q; Yang J; Li X; Xian L; Li W; Lin T; Cheng J; Lin Q; Xu X; Li Q; Lin Y; Zhou M; Shen E
Cancer Immunol Immunother; 2022 Feb; 71(2):277-287. PubMed ID: 34129052
[TBL] [Abstract][Full Text] [Related]
31. Biomarkers of aggressive pituitary adenomas.
Mete O; Ezzat S; Asa SL
J Mol Endocrinol; 2012 Oct; 49(2):R69-78. PubMed ID: 22822048
[TBL] [Abstract][Full Text] [Related]
32. Expression of Wnt4 in human pituitary adenomas regulates activation of the beta-catenin-independent pathway.
Miyakoshi T; Takei M; Kajiya H; Egashira N; Takekoshi S; Teramoto A; Osamura RY
Endocr Pathol; 2008; 19(4):261-73. PubMed ID: 19034702
[TBL] [Abstract][Full Text] [Related]
33. Tumor-Associated Macrophages: New Horizons for Pituitary Adenoma Researches.
Han C; Lin S; Lu X; Xue L; Wu ZB
Front Endocrinol (Lausanne); 2021; 12():785050. PubMed ID: 34925244
[TBL] [Abstract][Full Text] [Related]
34. Adrenocorticotropic hormone secreting pituitary adenomas: analysis of growth fraction using the MIB-1 antibody.
Mastronardi L; Guiducci A; Spera C; Puzzilli F; Liberati F; Ruggeri A; Peciarolo A
Tumori; 2000; 86(3):229-32. PubMed ID: 10939604
[TBL] [Abstract][Full Text] [Related]
35. Phosphorylated EGFR (pEGFR T693) as a Novel Predictor of Recurrence in Non-Functioning Pituitary Adenomas.
Rai A; Das L; Mukherjee KK; Dhandapani S; Tripathi M; Ahuja CK; Radotra BD; Dutta P
Front Endocrinol (Lausanne); 2021; 12():708111. PubMed ID: 34295309
[TBL] [Abstract][Full Text] [Related]
36. Proliferation markers and cell cycle inhibitors in pituitary adenomas.
Saeger W
Front Horm Res; 2004; 32():110-26. PubMed ID: 15281342
[TBL] [Abstract][Full Text] [Related]
37. Differential expression of cyclin D1 in human pituitary tumors: relation to MIB-1 and p27/Kip1 labeling indices.
Hewedi IH; Osman WM; El Mahdy MM
J Egypt Natl Canc Inst; 2011 Dec; 23(4):171-9. PubMed ID: 22776845
[TBL] [Abstract][Full Text] [Related]
38. Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis.
Chiloiro S; Doglietto F; Trapasso B; Iacovazzo D; Giampietro A; Di Nardo F; de Waure C; Lauriola L; Mangiola A; Anile C; Maira G; De Marinis L; Bianchi A
Neuroendocrinology; 2015; 101(2):143-50. PubMed ID: 25633744
[TBL] [Abstract][Full Text] [Related]
39. Aggressive Behavior in Silent Subtype III Pituitary Adenomas May Depend on Suppression of Local Immune Response: A Whole Transcriptome Analysis.
Richardson TE; Shen ZJ; Kanchwala M; Xing C; Filatenkov A; Shang P; Barnett S; Abedin Z; Malter JS; Raisanen JM; Burns DK; White CL; Hatanpaa KJ
J Neuropathol Exp Neurol; 2017 Oct; 76(10):874-882. PubMed ID: 28922848
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of DNA (Cytosine-5)-Methyltransferase 1 (DNMT1) And DNA (Cytosine-5)-Methyltransferase 3A (DNMT3A) Is Associated with Aggressive Behavior and Hypermethylation of Tumor Suppressor Genes in Human Pituitary Adenomas.
Ma HS; Wang EL; Xu WF; Yamada S; Yoshimoto K; Qian ZR; Shi L; Liu LL; Li XH
Med Sci Monit; 2018 Jul; 24():4841-4850. PubMed ID: 30002361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
